COVID‐19, chronic inflammatory respiratory diseases and eosinophils—Observations from reported clinical case series

Jeseňák, Miloš; Bánovčin, Peter; Diamant, Zuzana

doi:10.1111/all.14353

Cited by 45 publications

(56 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…From the results of the interrelation of the clinical symptoms and Lung CT imaging with the percentage of eosinophils, we found that COVID-19 patients with a low percentage of eosinophils were likely to develop a fever and pneumonia, which indicated an interrelation between both. Our findings had been supported by the previously reported studies in terms of eosinophils percentage in COVID-19 (16). Eosinophils percentage was considered to be a pro-inflammatory factor, playing a pleotropic role as regulatory cells involved in protective immunity, including antiviral responses and diverse physiological responses (17).…”

Section: Discussionsupporting

confidence: 88%

Clinical Characteristics and Eosinophils in Young SARS-CoV-2-Positive Chinese Travelers Returning to Shanghai

Yang

Zhao

Liu

et al. 2020

Front. Public Health

View full text Add to dashboard Cite

Background: The COVID-19 outbreak, which was first reported in Wuhan, China, in December 2019, began to spread throughout the world, and now involves over 200 countries. Methods: A total of 37 overseas young and middle-aged people, who tested as SARS-CoV-2 positive upon their return to Shanghai, were enrolled for an analysis of their clinical symptoms, blood routine indexes, and lung CT images. Results: The clinical symptoms were characterized by fever (51.4%), dry cough (13.5%), expectoration (27.0%), hypodynamia (21.6%), pharyngalia (10.8%), pharynoxerosis (8.1%), rhinobyon (13.5%), rhinorrhea (8.1%), muscular soreness (16.2%), and diarrhea (2.7%). In 16.2% of cases, no symptoms were reported. Fever was the most common symptom (51.40%). The pneumonic changes referred to the latticed ground glass imaging and similar white lung imaging accompanied by consolidated shadows. The rate of pneumonia was high (81.10%). We found that the exclusive percent of eosinophils was abnormally low. By analyzing the correlation of eosinophils, fever, and pneumonia, we found that the percentage of eosinophils was low in the COVID-19 patients afflicted with fever or pneumonia (P < 0.01). Additionally, pneumonia and fever were negatively correlated with the percentage of eosinophils and eosinophils/neutrophils ratio (P < 0.01, respectively), but not associated with pneumonia severity (P > 0.05). Fever was not correlated with pneumonia (P > 0.05). Conclusion: A low percentage of eosinophils may be considered as a biomarker of pneumonia of COVID-19, but not as a biomarker of pneumonia severity.

show abstract

Section: Discussionsupporting

confidence: 88%

Clinical Characteristics and Eosinophils in Young SARS-CoV-2-Positive Chinese Travelers Returning to Shanghai

Yang

Zhao

Liu

et al. 2020

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…On the other hand, recently described COVID-19-associated pediatric multi-system inflammatory syndrome shows several differences to the course of COVID-19 in adults and is highly specific for children (Deza Leon et al, 2020). Another interesting finding reported by several author groups is the eosinopenia associated with COVID-19 infections (Jesenak et al, 2020). Recent findings suggest that eosinophils have important antiviral properties (Flores-Torres et al, 2019).…”

Section: White Blood Cell Counts and Covid-19mentioning

confidence: 93%

Immune Parameters and COVID-19 Infection – Associations With Clinical Severity and Disease Prognosis

Jeseňák

Brndiarová

Urbancikova

et al. 2020

Front. Cell. Infect. Microbiol.

Self Cite

106

View full text Add to dashboard Cite

Severe acute respiratory syndrome caused by a novel 2019 coronavirus (SARS-CoV2) represents one of the most studied infectious diseases of today. The number of scientific reports and publications increases exponentially day by day. While the majority of infected subjects are asymptomatic or show mild symptoms, there is an important proportion of patients who requires hospitalization and, sometimes, intensive care. Immune response to novel coronavirus is complex, involves both innate and adaptive immunity, and is biphasic. Significant differences were observed when comparing severe and non-severe patients. Analysis of the reported results from clinical trials clearly show an involvement of specific cellular immunity (predominantly leucopenia, decreased counts of CD3 + , CD4 + , and CD8 + T lymphocytes, changes of T cell compartment) and the so-called cytokine storm, which is associated with worsening of symptoms and the promotion of lung damage. An interesting finding regarding eosinopenia that can have both diagnostic and prognostic value is reported by some authors. Examination of selected immune parameters could help to identify severe patients with the risk of unfavorable course of the disease, predict the prognosis and recognize improvement in the clinical status. Moreover, detailed analysis of the immune changes could help to select novel prospective therapeutic strategies.

show abstract

“…These findings suggest that severe asthmatics are not at Moreover, we may speculate of the consequence of blood eosinophils reduction induced by anti-IL5 agents, as more than 70% of infected patients were treated with them: Eosinopenia has been reported in 52%-90% of COVID-19 patients worldwide, and it has been suggested as a risk factor for more severe COVID-19. 9…”

mentioning

confidence: 99%

COVID‐19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments

Heffler

Detoraki

Contoli

et al. 2020

Allergy

View full text Add to dashboard Cite

To the Editor, Since the end of February 2020, Italy, first non-Asian Country, has reported an ever increasing number of COronaVIrus Disease 19 (COVID-19) patients, which has reached over 200 000 confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infected subjects, resulting in more than 34 000 deaths (data updated to June 19th, 2020 1). Patients with asthma are potentially more severely affected by SARS-CoV-2 infection and respiratory viruses are known to be associated with severe adverse asthma outcomes, including increased risk of asthma exacerbation episodes. 2 Nonetheless, according to the epidemiological studies published so far, asthma is not among the most common clinical conditions in COVID-19 patients. 3 About 5%-10% of asthmatics are severe, 4 and one would expect increased vulnerability to SARS-CoV-2 infection, but no data are so far available to confirm this hypothesis. We investigated the incidence of COVID-19, describing its clinical course, in the population of the Severe Asthma Network in Italy (SANI), one of the largest registry for severe asthma worldwide, 5 and in an additional Center (Azienda Ospedaliero Univeristaria di Ferrara, Ferrara, Italy). All centres have been contacted and inquired to report confirmed or highly suspect cases of COVID-19 (ie, patients with symptoms, laboratory findings and lung imaging typical of COVID-19 but without access to nasopharyngeal or oropharyngeal swab specimens because of clinical contingencies/emergency) among their cohorts of severe asthma. Demographic and clinical have been obtained from the

show abstract

COVID‐19, chronic inflammatory respiratory diseases and eosinophils—Observations from reported clinical case series

Abstract: A point mutation in the mma3 gene is responsible for impaired methoxymycolic acid production in Mycobacterium bovis BCG strains obtained after 1927.

Cited by 45 publications

References 8 publications

Clinical Characteristics and Eosinophils in Young SARS-CoV-2-Positive Chinese Travelers Returning to Shanghai

Clinical Characteristics and Eosinophils in Young SARS-CoV-2-Positive Chinese Travelers Returning to Shanghai

Immune Parameters and COVID-19 Infection – Associations With Clinical Severity and Disease Prognosis

COVID‐19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments

Contact Info

Product

Resources

About